Real-world safety of nusinersen in Japan: results from an interim analysis of a post-marketing surveillance and safety database.

Takafumi Wataya,Sakura Takasaki,Misuzu Hoshino,Haruki Makioka, Genshu Nakamura,Naoto Matsuda

The International journal of neuroscience（2021）

引用 8|浏览3
暂无评分
摘要
In this interim analysis of the PMS and Biogen safety database, nusinersen had a favourable benefit-risk profile in Japanese patients with SMA.
更多
查看译文
关键词
Benefit–risk profile,drug safety,nusinersen,post-marketing,spinalmuscular atrophy,surveillance
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要